Aytu BioScience Stock Forecast, Price & News

Aytu BioScience's stock was trading at $1.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AYTU shares have decreased by 29.6% and is now trading at $0.9503.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu BioScience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aytu BioScience.

Aytu BioScience is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Aytu BioScience.

Aytu BioScience, Inc. (NASDAQ:AYTU) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. The business had revenue of $8.16 million for the quarter, compared to the consensus estimate of $7 million. Aytu BioScience had a negative net margin of 49.29% and a negative return on equity of 37.62%.
View Aytu BioScience's earnings history.

Aytu BioScience's stock reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of Aytu BioScience stock prior to the reverse split would have 5 shares after the split.

2 Wall Street analysts have issued 1 year price targets for Aytu BioScience's shares. Their forecasts range from $3.00 to $5.00. On average, they expect Aytu BioScience's stock price to reach $4.00 in the next year. This suggests a possible upside of 320.9% from the stock's current price.
View analysts' price targets for Aytu BioScience.

Aytu BioScience saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 11,450,000 shares, an increase of 129.0% from the September 15th total of 5,000,000 shares. Based on an average daily trading volume, of 4,440,000 shares, the days-to-cover ratio is presently 2.6 days.
View Aytu BioScience's Short Interest.

Some companies that are related to Aytu BioScience include Homology Medicines (FIXX), AMAG Pharmaceuticals (AMAG), Albireo Pharma (ALBO), Urogen Pharma (URGN), Odonate Therapeutics (ODT), Aprea Therapeutics (APRE), MannKind (MNKD), Ardelyx (ARDX), ZIOPHARM Oncology (ZIOP), BeyondSpring (BYSI), Amryt Pharma (AMYT), Molecular Templates (MTEM), Neoleukin Therapeutics (NLTX), Prothena (PRTA) and Clovis Oncology (CLVS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioScience investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Ibio (IBIO), Matinas BioPharma (MTNB), BioNano Genomics (BNGO) and SCYNEXIS (SCYX).

Aytu BioScience trades on the NASDAQ under the ticker symbol "AYTU."

Aytu BioScience's stock is owned by many different institutional and retail investors. Top institutional shareholders include Beech Hill Advisors Inc. (0.02%). Company insiders that own Aytu BioScience stock include Armistice Capital Master Fund, David A Green and Joshua R Disbrow.
View institutional ownership trends for Aytu BioScience.

AYTU stock was bought by a variety of institutional investors in the last quarter, including Beech Hill Advisors Inc.. Company insiders that have bought Aytu BioScience stock in the last two years include Armistice Capital Master Fund, and Joshua R Disbrow.
View insider buying and selling activity for Aytu BioScience.

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AYTU stock can currently be purchased for approximately $0.95.

Aytu BioScience has a market capitalization of $119.58 million and generates $27.63 million in revenue each year. The company earns $-13,620,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. Aytu BioScience employs 61 workers across the globe.

The official website for Aytu BioScience is aytubio.com.

Aytu BioScience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]